Twice-Daily Aclidinium Bromide/formoterol Fumarate Fixed-Dose Combination: Lung Function Improvements In The Augment COPD Trial In Patients With Moderate To Severe COPD

被引：0
作者：
D'Urzo, A. D. [1 ]
Rennard, S. I. [2 ]
Kerwin, E. M. [3 ]
Mergel, V. [4 ]
Leselbaum, A. [5 ]
Caracta, C. [4 ]
机构：
[1] Univ Toronto, Toronto, ON, Canada
[2] Univ Nebraska Med Ctr, Omaha, NE USA
[3] Clin Res Inst, Medford, OR USA
[4] Forest Res Inst, Jersey City, NJ USA
[5] Almirall SA, Barcelona, Spain
来源：
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE | 2014年 / 189卷
关键词：
D O I：
暂无
中图分类号：
R4 [临床医学];
学科分类号：
1002 ; 100602 ;
摘要：
A3776
引用
收藏
页数：1
相关论文
共 50 条
  • [41] Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
    Singh, Dave
    Jones, Paul W.
    Bateman, Eric D.
    Korn, Stephanie
    Serra, Cristina
    Molins, Eduard
    Caracta, Cynthia
    Gil, Esther Garcia
    Leselbaum, Anne
    BMC PULMONARY MEDICINE, 2014, 14
  • [42] Efficacy and safety of aclidinium bromide/formoterol fumarate fixed-dose combinations compared with individual components and placebo in patients with COPD (ACLIFORM-COPD): a multicentre, randomised study
    Dave Singh
    Paul W Jones
    Eric D Bateman
    Stephanie Korn
    Cristina Serra
    Eduard Molins
    Cynthia Caracta
    Esther Garcia Gil
    Anne Leselbaum
    BMC Pulmonary Medicine, 14
  • [43] Aclidinium/formoterol Fixed-Dose Combination Improves Bronchodilation And Is Well Tolerated In Patients With COPD: Results From The Acliform/COPD Study
    Singh, D.
    Jones, P. W.
    Bateman, E. D.
    Korn, S.
    Serra, C.
    Molins, E.
    Caracta, C.
    Leselbaum, A.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2014, 189
  • [44] Effects of twice-daily aclidinium bromide in COPD patients: A long-term extension of ACCORD-COPD
    D'Urzo, Anthony
    Kerwin, Edward
    Donohue, James
    Rennard, Stephen
    Gelb, Arthur
    Lakkis, Hassan
    Garcia Gil, Esther
    Caracta, Cynthia
    EUROPEAN RESPIRATORY JOURNAL, 2012, 40
  • [45] Twice-Daily Aclidinium Bromide In COPD Patients: Nighttime Symptoms And Rescue Medication Use In Accord COPD I
    Kerwin, E. M.
    Rennard, S. I.
    Gelb, A. F.
    Rekeda, L.
    Garcia Gil, E.
    Caracta, C.
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2011, 183
  • [46] Effect of aclidinium bromide on static lung function and hyperinflation in patients with moderate to severe COPD
    Watz, Henrik
    Beeh, Kai M.
    Magnussen, Helgo
    de Theresa, Luis
    Jarreta, Diana
    Caracta, Cynthia
    Garcia, Esther
    EUROPEAN RESPIRATORY JOURNAL, 2013, 42
  • [47] Safety of aclidinium bromide/formoterol fumarate fixed dose combination (FDC) in COPD: Pooled analyses of three phase III studies
    Korn, Stephanie
    Kerwin, Edward
    Donohue, James F.
    Shrestha, Pomy
    Leselbaum, Anne
    Lei, Alejhandra
    EUROPEAN RESPIRATORY JOURNAL, 2014, 44
  • [48] Evaluation of the Efficacy and Safety of Two Doses of Aclidinium and Formoterol in Fixed-Dose Combination in Patients With COPD: The ACLIFORM Study
    Singh, Dave
    Jones, Paul
    Bateman, Eric
    Korn, Stephanie
    Serra, Cristina
    Molins, Eduard
    Caracta, Cynthia
    Gil, Esther Garcia
    Leselbaum, Anne
    CHEST, 2014, 145 (03)
  • [49] Efficacy and Safety of a 12-week Treatment with Twice-daily Aclidinium Bromide in COPD Patients (ACCORD COPD I)
    Kerwin, Edward M.
    D'Urzo, Anthony D.
    Gelb, Arthur F.
    Lakkis, Hassan
    Garcia Gil, Esther
    Caracta, Cynthia F.
    COPD-JOURNAL OF CHRONIC OBSTRUCTIVE PULMONARY DISEASE, 2012, 9 (02) : 90 - 101
  • [50] Efficacy of Aclidinium Bromide 400 μg Twice Daily Compared With Placebo and Tiotropium in Patients With Moderate to Severe COPD
    Fuhr, Rainard
    Magnussen, Helgo
    Sarem, Kristina
    Ribera Llovera, Anna
    Kirsten, Anne-Marie
    Falques, Meritxell
    Caracta, Cynthia F.
    Garcia Gil, Esther
    CHEST, 2012, 141 (03) : 745 - 752
12345